Download this Paper Open PDF in Browser

Reverse-Payment Settlement Agreements Roundtable

ABA Antitrust Health Care Chronicle, 2013

21 Pages Posted: 13 Apr 2013 Last revised: 5 May 2015

Michael A. Carrier

Rutgers Law School

Howard Morse

Cooley Godward Kronish LLP

Eric Stock

Hogan Lovells

Kent Bernard

Fordham University School of Law

Karen Bokat

Wiley Rein & Fielding LLP

Date Written: March 20, 2013

Abstract

This roundtable explores issues presented by "reverse payment" settlements by which brand-name drug companies pay generic firms to delay entering the market. Kent Bernard, Karen Bokat, Michael Carrier, Howard Morse, and Eric Stock explore the history of the settlements, potential legislation, future enforcement efforts, activity in Europe, anticipated market behavior, and predictions about the Court's ruling in FTC v. Actavis.

Keywords: drug patents, reverse payments, settlements, patent, antitrust, pharmaceuticals, Hatch Waxman Act

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A. and Morse, Howard and Stock, Eric and Bernard, Kent and Bokat, Karen, Reverse-Payment Settlement Agreements Roundtable (March 20, 2013). ABA Antitrust Health Care Chronicle, 2013. Available at SSRN: https://ssrn.com/abstract=2246466

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Howard Morse

Cooley Godward Kronish LLP ( email )

United States

Eric Stock

Hogan Lovells ( email )

555 13th Street, NW
Washington, DC 20004
United States

Kent Bernard

Fordham University School of Law ( email )

8 Bayberry Lane
Westport, CT 06880
United States

Karen Bokat

Wiley Rein & Fielding LLP ( email )

United States

Paper statistics

Downloads
82
Rank
255,354
Abstract Views
896